Medesis Pharma (ALMDP) Stock Overview

Medesis Pharma S.A. operates as a biopharmaceutical company. The company's products include NanoLithium (NP03) for the treatment of Alzheimer's disease; NanosiRNA HD and NanoP42T to treat Huntington's disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma. The company was founded in 2003 and is based in Montpellier, France.